ChemoMetec A/S (CO:CHEMM) — Stock Price
ChemoMetec A/S (CO:CHEMM) is currently trading at Dkr466.40 DKK, up 8.47% today. Over the past 52 weeks, shares have ranged between Dkr236.80 and Dkr792.00. This page tracks ChemoMetec A/S's live share price on the CO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CHEMM stock market capitalisation.
ChemoMetec A/S (CHEMM) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ChemoMetec A/S's daily closing share price and trading volume on the CO exchange over the past year, giving a clear view of recent price momentum and liquidity.
ChemoMetec A/S Income Statement — Revenue, Profit & Earnings by Year
ChemoMetec A/S's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Dkr495.57 Million | Dkr407.87 Million | Dkr444.40 Million | Dkr428.39 Million | Dkr281.13 Million |
| Cost of Revenue | Dkr30.06 Million | Dkr40.27 Million | Dkr49.01 Million | Dkr44.14 Million | Dkr27.78 Million |
| Gross Profit | Dkr465.51 Million | Dkr367.60 Million | Dkr395.39 Million | Dkr384.25 Million | Dkr253.34 Million |
| Research & Development | Dkr10.37 Million | Dkr8.39 Million | Dkr7.16 Million | Dkr7.23 Million | Dkr6.49 Million |
| SG&A | — | — | — | Dkr41.30 Million | Dkr23.44 Million |
| Total Operating Expenses | Dkr217.83 Million | Dkr53.59 Million | Dkr51.18 Million | Dkr47.63 Million | Dkr137.32 Million |
| Operating Income | Dkr247.68 Million | Dkr178.78 Million | Dkr228.51 Million | Dkr201.53 Million | Dkr116.02 Million |
| EBITDA | Dkr247.68 Million | Dkr186.59 Million | Dkr245.38 Million | Dkr218.53 Million | Dkr126.63 Million |
| EBIT | Dkr236.52 Million | Dkr176.77 Million | Dkr231.45 Million | Dkr204.74 Million | Dkr113.65 Million |
| Interest Expense | Dkr624.00K | Dkr183.00K | Dkr1.09 Million | Dkr1.52 Million | Dkr918.00K |
| Income Before Tax | Dkr240.01 Million | Dkr176.59 Million | Dkr230.36 Million | Dkr203.22 Million | Dkr112.73 Million |
| Income Tax Expense | Dkr53.61 Million | Dkr40.30 Million | Dkr51.69 Million | Dkr43.75 Million | Dkr24.38 Million |
| Net Income | Dkr186.41 Million | Dkr136.28 Million | Dkr178.67 Million | Dkr159.47 Million | Dkr88.35 Million |
ChemoMetec A/S Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ChemoMetec A/S's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Dkr828.05 Million | Dkr676.67 Million | Dkr657.98 Million | Dkr501.27 Million | Dkr344.91 Million |
| Total Current Assets | Dkr543.16 Million | Dkr489.80 Million | Dkr492.66 Million | Dkr352.94 Million | Dkr244.36 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Dkr79.62 Million | Dkr69.08 Million | Dkr59.74 Million | Dkr65.87 Million | Dkr62.65 Million |
| Inventory | Dkr109.34 Million | Dkr119.50 Million | Dkr112.64 Million | Dkr66.79 Million | Dkr30.11 Million |
| Property, Plant & Equipment | — | — | Dkr82.69 Million | Dkr74.78 Million | Dkr42.50 Million |
| Goodwill | Dkr7.35 Million | Dkr0.00 | — | — | — |
| Total Liabilities | Dkr154.69 Million | Dkr111.36 Million | Dkr124.93 Million | Dkr144.07 Million | Dkr79.93 Million |
| Total Current Liabilities | Dkr146.99 Million | Dkr98.53 Million | Dkr119.19 Million | Dkr137.38 Million | Dkr71.97 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | Dkr-335.44 Million | Dkr-291.99 Million | Dkr-309.41 Million | Dkr-202.23 Million | Dkr-147.75 Million |
| Total Stockholder Equity | Dkr673.36 Million | Dkr565.32 Million | Dkr533.04 Million | Dkr357.20 Million | Dkr264.98 Million |
| Retained Earnings | Dkr664.70 Million | Dkr547.89 Million | Dkr515.62 Million | Dkr339.78 Million | Dkr247.57 Million |
ChemoMetec A/S Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ChemoMetec A/S generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Dkr207.45 Million | Dkr129.00 Million | Dkr154.15 Million | Dkr176.86 Million | Dkr107.90 Million |
| Capital Expenditures | Dkr29.87 Million | Dkr43.53 Million | Dkr40.82 Million | Dkr55.92 Million | Dkr24.62 Million |
| Free Cash Flow | Dkr177.58 Million | Dkr85.47 Million | Dkr113.33 Million | Dkr120.94 Million | Dkr83.28 Million |
| Investing Cash Flow | Dkr-85.52 Million | Dkr-43.49 Million | Dkr-40.83 Million | Dkr-56.05 Million | Dkr-24.68 Million |
| Financing Cash Flow | Dkr-74.96 Million | Dkr-105.72 Million | Dkr-2.92 Million | Dkr-69.01 Million | Dkr-26.04 Million |
| Dividends Paid | Dkr69.60 Million | Dkr104.42 Million | — | Dkr69.61 Million | Dkr26.10 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Dkr21.53 Million | Dkr17.21 Million | Dkr20.47 Million | Dkr20.04 Million | Dkr19.61 Million |
| Change in Cash | Dkr45.70 Million | Dkr-20.43 Million | Dkr107.55 Million | Dkr58.92 Million | Dkr53.17 Million |
ChemoMetec A/S Earnings History — EPS Actual vs. Analyst Estimates
Track ChemoMetec A/S's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 09, 2026 | — | — | — |
| May 05, 2026 | — | — | — |
| Dec 31, 2025 | — | 4.69 | — |
| Sep 30, 2025 | — | 3.98 | — |
| Jun 30, 2025 | — | -0.96 | — |
| May 07, 2025 | 3.64 | 3.17 | +14.83% |
| Feb 05, 2025 | 4.20 | 3.54 | +18.64% |
| Nov 07, 2024 | 3.56 | 2.88 | +23.61% |